Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy.

NCT00418743 is registered in ClinicalTrials.gov with Groupe Francais De Pneumo-Cancerologie as lead sponsor.

NCT NCT00418743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00418743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy.
Lead sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2005
Completion date
May 31, 2010
Enrollment
138 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer